Table 1.
Baseline characteristics of the study participants.
| Variables | AXOS (n = 24) | Placebo (n = 24) | P |
|---|---|---|---|
| Sex, male/female | 6/18 | 6/18 | |
| Age, y | 36.1 ± 12.9 | 35.7 ± 11.0 | .905 |
| Weight, kg | 72.7 ± 12 | 72 .5 ± 11.7 | .912 |
| Body mass index, kg/m2 | 24.7 ± 3.1 | 24.2 ± 2.3 | .532 |
| Body fat, % | 25.4 ± 7.2 | 25.5 ± 8.4 | .861 |
| Fat mass, kg | 18.4 ± 5.7 | 19.2 ± 7.6 | .952 |
| Systolic blood pressure, mmHg | 116 ± 9 | 115 ± 11 | .532 |
| Diastolic blood pressure, mmHg | 79 ± 5 | 76 ± 8 | .125 |
| Fasting glucose, mmol/L | 4.8 ± 0.3 | 5.0 ± 0.3 | .067 |
| OGTT 2h plasma glucose, mmol/L | 4.7 ± 1.2 | 4.9 ± 1.1 | .503 |
| Whole-gut transit time, h | 70.8 ± 26 | 80.2 ± 21 | .084 |
Values are given as means ± SD. Group differences were assessed using independent Student’s t-test. OGTT oral glucose tolerance test, AXOS Arabinoxylan-Oligosaccharides